MULTIDISCIPLINARY THORACIC CANCERS SYMPOSIUM

BRINGING PERSONALIZED CARE TO YOUR PATIENTS

HILTON SAN DIEGO BAYFRONT SAN DIEGO | MARCH 14-16, 2019

News Briefing: Highlights from the 2019 Multidisciplinary Thoracic Cancers Symposium

About the Symposium

March 14-16, Hilton San Diego Bayfront, <u>www.thoracicsymposium.org</u>

Co-sponsored by: American Society for Radiation Oncology (ASTRO) American Society of Clinical Oncology (ASCO) The Society of Thoracic Surgeons (STS)

Email press@astro.org with questions or interview requests.



Embargo Policy

Embargoes for the three studies in this briefing are now lifted.

All other studies to be presented at the symposium are embargoed until 8:00 a.m. Pacific time (11:00 a.m. Eastern time) on Thursday, March 14, 2019. Abstracts will be posted online at that time.



News Briefing: Highlights from the 2019 Multidisciplinary Thoracic Cancers Symposium

Moderator: Charles B. Simone, II, MD, New York Proton Center

Improved Overall Survival with Local Consolidative Therapy in Oligometastatic Non-Small Cell Lung Cancer: Results from a Cohort of 194 Patients with Synchronous Disease (Abstract 1)

Erin Corsini, MD, University of Texas MD Anderson Cancer Center

The Impact of Structured, Prospective Exposure to the NCCN Guidelines when Making Treatment Decisions: Improved Metrics of Guideline-Concordant Care for Patients with Non-Small Cell Lung Cancer (Abstract 5)

Susan Wu, MD, University of California, San Francisco

The Impact of the Stage III Randomized Trial by Takahashi et al. on the Use of Prophylactic Cranial Irradiation (PCI) in Patients with Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) (Abstract 3)

Olsi Gjyshi, MD, PhD, University of Texas MD Anderson Cancer Center





Improved Overall Survival with Local Consolidative Therapy in Oligometastatic Non-Small Cell Lung Cancer:

Results from a Cohort of 194 Patients with Synchronous Disease

Kyle G. Mitchell¹, Ahsan Farooqi², Ethan B. Ludmir², <u>Erin M. Corsini¹</u>, Ara A. Vaporciyan¹, Stephen G. Swisher¹, John V. Heymach³, Jianjun Zhang³, Daniel R. Gomez², and Mara B. Antonoff¹

¹Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center ²Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center ³Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center





Disclosure for Dr. Corsini

- Employer: The University of Texas MD Anderson Cancer Center
- I have nothing to disclose.






Oligometastatic NSCLC

Advanced NSCLC

- Frequently present at diagnosis
- Associated with dismal prognosis

Oligometastatic state: limited disease burden¹

- Distinct tumor biology^{2,3}
- Spectrum of associated outcomes



¹Hellman J Clin Oncol 1995; ²Wong Cancer 2016; ³Lussier PLoS One 2011; Figure: Gomez 2016




Oligometastatic NSCLC

Advanced NSCLC

- Frequently present at diagnosis
- Associated with dismal prognosis

Oligometastatic state: limited disease burden¹

- Distinct tumor biology^{2,3}
- Spectrum of associated outcomes



¹Hellman J Clin Oncol 1995; ²Wong Cancer 2016; ³Lussier PLoS One 2011; Figure: Gomez 2016



Objectives and Hypothesis

Objectives: In synchronous oligometastatic (≤ 3 sites) NSCLC

- Characterize survival outcomes associated with LCT
- Define subgroups deriving greatest therapeutic benefit

Hypothesis: Local consolidative therapy → improved overall survival



Clinicopathologic Characteristics (N=194)

| Variable | N (%) or Median (IQR) |
|---|-----------------------------------|
| Age (years) | 62 (57-69) |
| Sex (M) | 111 (57%) |
| Histology Adenocarcinoma Squamous NSCLC NOS | 149 (77%) 34 (18%) 11 (6%) |
| Thoracic Stage | 37 (19%) 42 (22%) 115 (59%) |

| Variable | N (%) or Median (IQR) |
|------------------------|-----------------------|
| # of Metastatic Sites | |
| 1 | 57 (29%) |
| 2 | 103 (53%) |
| 3 | 34 (18%) |
| Location of Metastases | |
| Brain | 86 (44%) |
| Bone | 51 (26%) |
| Adrenal | 36 (19%) |
| Liver | 7 (4%) |



Clinicopathologic Characteristics (N=194)

| Variable | N (%) or Median (IQR) |
|---|-----------------------------------|
| Age (years) | 62 (57-69) |
| Sex (M) | 111 (57%) |
| Histology Adenocarcinoma Squamous NSCLC NOS | 149 (77%) 34 (18%) 11 (6%) |
| Thoracic Stage | 37 (19%) 42 (22%) 115 (59%) |

| Variable | N (%) or Median (IQR) | |
|------------------------|-----------------------|--|
| # of Metastatic Sites | | |
| 1 | 57 (29%) | |
| 2 | 103 (53%) | |
| 3 | 34 (18%) | |
| Location of Metastases | | |
| Brain | 86 (44%) | |
| Bone | 51 (26%) | |
| Adrenal | 36 (19%) | |
| Liver | 7 (4%) | |

Comprehensive LCT to all sites (cLCT):

121 (62%)

Subcomprehensive or No LCT to metastases (no LCT):

73 (38%)






Survival Outcomes (N=194)

| Group | N | MST | 95% CI |
|-------------------|-----|-----------|--------------|
| Comprehensive LCT | 121 | 29 months | 25-42 months |
| No cLCT | 73 | 23 months | 16-35 months |

| Group | Ν | 1yOS | 3yOS | 5yOS |
|-------------------|-----|------|------|------|
| Comprehensive LCT | 121 | 85% | 43% | 32% |
| No cLCT | 73 | 72% | 35% | 19% |

Median follow-up duration 52 months (IQR 48-66)




#THORACIC19


Survival Outcomes Among Patients Undergoing cLCT (N=121)

Associated with poorer survival:

- Squamous histology
- Higher intrathoracic stage
- Bone metastases




Patterns of Treatment Failure (cLCT, N=121)





Patterns of Treatment Failure (cLCT, N=121)





Conclusions

- Local consolidative therapy to all sites of disease associated with improved overall survival
 - 3-year OS: 43%
 - 5-year OS: 32%
- Best outcomes: Adenocarcinoma, thoracic stage I/II, no bone metastases
- Further work needed to characterize in context of contemporary systemic therapies

The Impact of Structured, Prospective Exposure to the NCCN Guidelines when Making Treatment Decisions: Improved Metrics of Guideline-Concordant Care for Patients with Non-Small Cell Lung Cancer

Susan Wu¹, Ann A. Lazar¹, Matthew A. Gubens¹, Collin M. Blakely¹, Alexander R. Gottschalk¹, Adam A. Garsa², David M. Jablons¹, Thierry M. Jahan¹, Victoria E.H. Wang¹, Taylor L. Dunbar¹, Rosa Paz¹, Linsey Curran¹, William Guthrie³, Jeffrey Belkora¹, and Sue S. Yom¹

¹University of California, San Francisco ²University of Southern California ³Patients with Power, San Francisco



Disclosure for Dr. Wu

• Employer: University California, San Francisco





Background

- For patients newly diagnosed with cancer, discussions regarding treatment modalities and side effects are complex
- NCCN guidelines are readily available to physicians
- For patients, clear guidelines are not easily accessible
- Decision support tools improve patient knowledge and satisfaction
- These tools may help patients better understand the nuances of various treatment options, and become more active participants in the decision making process





• To assess the feasibility and impact of an evidence-based decision aid for patients with non-small cell lung cancer





Primary Objective


Does structured exposure to NCCN guidelines impact any of the following six practice patterns?

- 1. Smoking cessation counseling reinforced with a specific plan
- 2. Stage IB, IIA, IIB: use of adjuvant chemotherapy after surgery
- 3. Stage III undergoing surgery, and
- 4. Stage III not undergoing surgery: pathological staging of the mediastinum prior to initiating treatment
- 5. Stage III not undergoing surgery: concurrent chemoradiation given up front
- 6. Stage IV: molecular testing for EGFR and ALK mutations prior to initiation of systemic therapy



Methods: Tool development

Phase I: Development of the web-based tool





Methods: Implementation

- Patients were introduced to the tool by a trained coordinator at the time of initial consultation with one of five thoracic oncologists
- If requested by the patient, the trained coordinator facilitated discussion between the patient and oncologist based on the treatment options
- Patients consented to have their use of the tool (based on number of log-ins) recorded for one year following consultation

Results: Patient Characteristics

- 76 patients enrolled
- Compared to a retrospective cohort of 159 patients


| Characteristic | Prospective Cohort | Comparison Cohort |
|-------------------------------------|-----------------------|----------------------|
| Median age at study (range) | 68 (47-88) | 68 (41-88) |
| Female | 32 (42%) | 67 (42%) |
| History of tobacco use Histology | 57 (75%) | 115 (72%) |
| Adenocarcinoma | 59 (78%) | 107 (67%) |
| Squamous cell carcinoma | 14 (18%) | 28 (18%) |
| Adenosquamous | 2 (3%) | 7 (4%) |
| Other (large cell, NOS) | 0 (0%) | 16 (10%) |
| Not biopsied | 3 (4%) | 1 (1%) |
| AJCC stage group | | |
| IA | 20 (26%) | 20 (13%) |
| IB | 8 (11%) | 16 (10%) |
| IIA | 5 (7%) | 2 (1%) |
| IIB | 3 (4%) | 8 (5%) |
| IIIA | 9 (12%) | 33 (21%) |
| IIIB | 8 (11%) | 14 (9%) |
| IV | 23 (30%) | 66 (42%) |





Results: Patient Use

- 66 patients (84%) accessed the tool following consultation
- The tool was accessed a median of 3 times following consultation (range 0-20)





Results: Significant Findings

Among patients exposed to the evidence-based guidelines:

| Increase in smoking cessation counseling/intervention | 80% vs. 40% | p < 0.001 |
|---|-------------------------|-----------|
| Decrease in adjuvant chemotherapy for patients with stage IB/IIA/IIB disease | 0% (0/8) vs. 50% (6/12) | p = 0.02 |
| Driven primarily by patients with stage IB disease, resected with negative margins | 0% (0/6) vs. 100% (4/4) | p = 0.04 |
| Increase in molecular testing prior to initiation of systemic therapy in patients with Stage IV disease | 96% vs. 68% | p = 0.01 |



Results

- No difference in the rate of pathologic mediastinal staging in patients with stage III disease undergoing surgery (p = 0.70) or non-operative management (p = 0.55)
- No difference in up-front use of chemoradiation in stage III patients with nonoperative disease (p = 0.55)



Conclusions

- Structured exposure to the NCCN guidelines improved guideline concordance with regard to smoking cessation and testing for molecular markers in patients with metastatic disease
- Educational tools may empower patients to be more active partners in decisionmaking, and in some cases meaningfully impact patient care



Acknowledgments

Principal Investigator: Sue S. Yom

Statistician: Ann Lazar

Radiation Oncology: Alexander Gottschalk, Adam Garsa, Sue Yom

Thoracic Surgery: David Jablons

Thoracic Oncology: Matthew Gubens, Collin Blakely, Thierry Jahan, Victoria Wang

UCSF Institute for Health Policy: Jeffrey Belkora

Taylor Dunbar, Rosa Paz, Linsey Curran, William Guthrie



The Impact of the Stage III Randomized Trial by Takahashi *et al.* on the Use of Prophylactic Cranial Irradiation (PCI) in Patients with Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

<u>Olsi Gjyshi</u>, Ethan B. Ludmir, Todd A. Pezzi, David Boyce-Fappiano, Timur Mitin, and Steven H. Lin

The University of Texas MD Anderson Cancer Center



Disclosure for Dr. Gjyshi

- Employer: The University of Texas MD Anderson Cancer Center
- I have nothing to disclose.






Background

- Small cell lung cancer (SCLC) is a highly aggressive tumor
- The mainstay of treatment is chemotherapy +/- radiation to the chest
 - Limited stage (LS-SCLC) vs. extensive stage (ES-SCLC)
- Despite recent advancements in cancer medicine, SCLC continues to have poor outcomes
- Brain metastases are very common in SCLC, particulary in those with extensive stage disease
- Prophylactic Cranial Irradiation (PCI) as a practice






2019 MULTIDISCIPLINARY THORACIC CANCERS SYMPOSIUM


💓 #THORACIC19

Survey: Thoracic Radiation Oncologists from US Academic Institutions (N=49)






Follow-up Nationwide Survey: ASTRO-registered Radiation Oncologists (N=431)






Follow-up Nationwide Survey: ASTRO-registered Radiation Oncologists (N=431)



#THORACIC19

Follow-up Nationwide Survey: ASTRO-registered Radiation Oncologists (N=431)





Conclusion/Summary

- The practice of PCI in patients with ES-SCLC is rapidly evolving
- Close MRI surveillance and PCI are both acceptable options, with MRI Surveillance becoming more predominant since the publication of Takahashi et al., 2017
- Careful consideration should be given to future studies/trials that are planning on investigating the role of PCI in this patient population
- Increasing awareness about the current body of literature on the topic is important for physicians and patients in making an educated decision



Expert Perspective

Dr. Charles B. Simone, II Chief Medical Officer, New York Proton Center

#THORACIC19



Please use the "Question" tab in GoToWebinar to submit your questions.



Interview Requests & Other Questions

press@astro.org

703-286-1600

Slides and a recording of this briefing will be available online: <u>www.astro.org/thoracicpress</u>

